BTK inhibitors are clinically employed as targeted therapies for DLBCL, downregulating the BCR signaling pathway (Advani et al. 2013; Ondrisova and Mraz 2020; Nakhoda et al. 2023). Here, BTK is linked to diffuse large B-cell lymphoma.